Table 2.
Relative risk of subsequent brain metastasis of stage IIIB or IV NSCLC patients.
| Unadjusted RR (95% CI) | P-value | Adjusted RR (95% CI) | P-value | |
|---|---|---|---|---|
| Age | ||||
| <30 vs. 40–49 | 1.869 (1.610–2.169) | <0.0001 | 2.105 (1.815–2.445) | <0.0001 |
| <30 vs. 50–59 | 2.907 (2.494–3.401) | <0.0001 | 2.994 (2.570–3.496) | <0.0001 |
| <30 vs. 60–69 | 4.049 (3.322–4.926) | <0.0001 | 3.846 (3.165–4.695) | <0.0001 |
| <30 vs. ≥70 | 3.690 (2.525–5.405) | <0.0001 | 3.521 (2.421–5.128) | <0.0001 |
| Sex (female vs. male) | 2.364 (2.110–2.653) | <0.0001 | 1.821 (1.600–2.070) | <0.0001 |
| Anticoagulation (non-user vs. user) | 0.873 (0.860–1.236) | 0.445 | 0.905 (0.642–1.277) | 0.571 |
| COPD (absence vs. presence) | 2.083 (1.376–3.165) | 0.001 | 1.170 (0.769–1.779) | 0.465 |
| First-line systemic treatment (TT vs. CC) | 2.427 (2.169–2.717) | <0.0001 | 1.976 (1.745–2.242) | <0.0001 |
Abbreviations: RR, relative risk; CI, confidence interval; CC, cytotoxic chemotherapy; TT, targeted therapy; COPD, chronic obstructive pulmonary disease.